Clinical Safety Evaluation and Preliminary Efficacy Study of Subcutaneous Myografts Transplantation

Sponsor
National Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation, China
Study ID
NCT07426068
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Amyotrophy
  • Metabolic Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Autologous differentiated myocyte transplantation — BIOLOGICAL
    Autologous differentiated myocytes will be prepared from each participant and transplanted subcutaneously. All enrolled participants will receive the same intervention and will be followed longitudinally for safety, feasibility, and outcome assessments.

Study Details

This study aims to apply autologous differentiated myocyte subcutaneous transplantation in patients with muscle atrophy to explore its safety, feasibility, and efficacy.

Key Dates

First listed
Feb 23, 2026
Start date
Jul 1, 2026
Status verified
Feb 2026
Primary completion
Feb 1, 2028
Completion
Feb 1, 2028

Study Design

Enrollment
6 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Autologous differentiated myocyte transplantation
    Each participant will complete the same set of assessments both before and after the intervention. A within-subject pre-post comparison will be performed to evaluate individualized responses and temporal changes induced by the subcutaneous muscle graft intervention.

Primary Outcome Measure

Blood pressure [ Time Frame: Perioperative ]

Central Contacts

Related Studies